伴容量超负荷急性肾损伤患者肾脏替代治疗模式的经济学分析
该研究采用决策分析模型,从美国医疗付费方视角比较伴容量超负荷(FO)的急性肾损伤(AKI)患者初始启动连续性肾脏替代治疗(CRRT)与间歇性血液透析(IHD)的健康结局与费用。模型包括90天住院阶段(FO、容量控制、死亡三状态)及此后终身阶段(透析独立、透析依赖、肾移植、死亡四状态)。90天时CRRT组生存率59.2% vs IHD组57.5%,幸存者透析依赖率CRRT 5.5% vs IHD 6.9%;CRRT组医疗费用高2.7%(+2,836美元)。终身分析中,初始CRRT较初始IHD增加0.313生命年和0.187质量调整生命年(QALY),增量成本为每QALY增加10,429美元。敏感性分析结果稳健,作者认为该分析为CRRT作为初始模式提供了经济学依据,但需未来研究证实。
要点
- 90天时,初始CRRT组生存率59.2%,初始IHD组57.5%;幸存者透析依赖率CRRT 5.5% vs IHD 6.9%。
- 90天医疗费用CRRT组较IHD组高2.7%(+2,836美元)。
- 终身分析中,初始CRRT较初始IHD增加0.313生命年和0.187个QALY。
- 幸存者透析依赖率降低带来的节省为13,437美元,但未能完全抵消CRRT的增量成本(+1,956美元)和透析独立生存的增量成本(+12,830美元)。
- CRRT较IHD的增量成本效果比为每QALY增加10,429美元,敏感性分析结果稳健。
适用人群与场景
- 需要肾脏替代治疗的伴容量超负荷的急性肾损伤(AKI)患者,场景为ICU。
研究设计与关键结果
- 研究设计:决策分析模型,从美国医疗付费方视角比较初始CRRT与初始IHD,模型包括90天住院阶段(FO、容量控制、死亡三个健康状态)和此后终身阶段(透析独立、透析依赖、肾移植、死亡四个健康状态),模型参数来源于当前文献并进行了敏感性分析。
- 90天结局:初始CRRT组生存率59.2% vs 初始IHD组57.5%;幸存者透析依赖率CRRT 5.5% vs IHD 6.9%。
- 90天费用:CRRT组医疗费用较IHD组高2.7%(+2,836美元)。
- 终身结局:初始CRRT较初始IHD增加0.313生命年和0.187个QALY。
- 费用分解:初始CRRT因幸存者透析依赖率较低节省13,437美元,但未能完全抵消CRRT的增量成本(+1,956美元)和透析独立生存的增量成本(+12,830美元)。
- 增量成本效果:CRRT较IHD的增量成本为每QALY增加10,429美元;敏感性分析显示结果稳健。
证据类型、等级与局限
- 证据类型:决策分析模型(基于文献参数的建模研究)。
- 局限:作者指出该发现需在未来研究中证实。
对床旁实践的改变
- 作者认为,该分析为CRRT作为需要肾脏替代治疗的伴容量超负荷AKI患者的初始模式选择提供了经济学依据。
- 作者指出该发现需在未来研究中证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Acute kidney injury (AKI) and fluid overload (FO) are among the top reasons to initiate intermittent hemodialysis (IHD) or continuous renal replacement therapy (CRRT). Prior research suggests CRRT provides more precise volume control, but whether CRRT is cost-effective remains unclear. We assessed the cost-effectiveness of CRRT for volume control compared with IHD from a U.S. healthcare payer perspective.
DESIGN: Decision analytical model comparing health outcomes and healthcare costs of CRRT versus IHD initiation for AKI patients with FO. The model had an inpatient phase (over 90-d) followed by post-discharge phase (over lifetime). The 90-day phase had three health states: FO, fluid control, and death. After 90 days, surviving patients entered the lifetime phase with four health states: dialysis independent (DI), dialysis dependent (DD), renal transplantation, and death. Model parameters were informed by current literature. Sensitivity analyses were performed to evaluate results robustness to parametric uncertainty.
PATIENTS OR SUBJECTS: AKI patients with FO.
INTERVENTIONS: IHD or CRRT.
MEASUREMENTS AND MAIN RESULTS: The 90-day horizon revealed better outcomes for patients initiated on CRRT (survival: CRRT 59.2% vs IHD 57.5% and DD rate among survivors: CRRT 5.5% vs IHD 6.9%). Healthcare cost was 2.7% (+$2,836) higher for CRRT. Over lifetime, initial CRRT was associated with +0.313 life years (LYs) and +0.187 quality-adjusted life years (QALYs) compared with initial IHD. Even though important savings were observed for initial CRRT with a lower rate of DD among survivors (-$13,437), it did not fully offset the incremental cost of CRRT (+$1,956) and DI survival (+$12,830). The incremental cost-per-QALY gained with CRRT over IRRT was +$10,429/QALY. Results were robust to sensitivity analyses.
CONCLUSIONS: Our analysis provides an economic rationale for CRRT as the initial modality of choice in AKI patients with FO who require renal replacement therapy. Our finding needs to be confirmed in future research.
参考来源
- Ethgen O, Murugan R, Echeverri J, et al. Economic Analysis of Renal Replacement Therapy Modality in Acute Kidney Injury Patients With Fluid Overload. Crit Care Explor. 2023. PMID: 37637357. doi:10.1097/CCE.0000000000000921
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。